Avacta Group (AVCT) Short Positions
Add to Alert list

Active Short Positions

Holder Position Change Date
No active short positions

Historical Short Positions

Holder Position Change (%) Date
GSA Capital Partners LLP 0.59% 0 31-Jul-2025 View History
GSA Capital Partners LLP 0.67% 0 24-Jul-2025 View History
GSA Capital Partners LLP 0.78% 0 10-Jul-2024 View History
GSA Capital Partners LLP 0.81% 0 28-May-2024 View History
GSA Capital Partners LLP 0.7% 0 09-May-2024 View History
GSA Capital Partners LLP 0.6% 0 24-Apr-2024 View History
GSA Capital Partners LLP 0.5% 0 16-Apr-2024 View History
Jupiter Investment Management Limited 0.3% 18-Oct-2022 View History
Jupiter Investment Management Limited 0.73% 10-Oct-2022 View History
Jupiter Investment Management Limited 0.61% 28-Apr-2022 View History
Jupiter Investment Management Limited 0.58% 03-Mar-2022 View History
Jupiter Investment Management Limited 0.68% 01-Mar-2022 View History
Jupiter Investment Management Limited 0.88% 22-Feb-2022 View History
Jupiter Investment Management Limited 1.03% 03-Feb-2022 View History
Bronte Capital Management Pty Ltd 0.5% 21-Jan-2022 View History
Bronte Capital Management Pty Ltd 0.49% 12-Jan-2022 View History
Jupiter Investment Management Limited 0.94% 22-Dec-2021 View History
Bronte Capital Management Pty Ltd 0.51% 06-Dec-2021 View History
Jupiter Investment Management Limited 0.84% 02-Nov-2021 View History
Jupiter Investment Management Limited 0.75% 20-Aug-2021 View History
Jupiter Investment Management Limited 0.63% 12-Aug-2021 View History
Jupiter Investment Management Limited 0.52% 07-Jul-2021 View History

Avacta Group plc is a United Kingdom-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. The Company has two segments: Therapeutics and Diagnostics. The Therapeutics segment is a clinical stage oncology biotech division harnessing therapeutic platforms to develop novel, highly targeted cancer drugs. The Diagnostics segment is focused on supporting healthcare professionals and broadening access to diagnostics.

It has two platforms: preICISION and Affimer. The Company's preICISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preICISION platform harnesses this tumor specific protease to activate preICISION peptide drug conjugates and preICISION antibody/Affimer drug conjugates in the tumor microenvironment. Its lead preICISION program AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies.

Avacta Group share price launched at 5,448p in 2003. 

Note: This description is in part generated by AI and not an endorsement by or the opinion of Investegate
UK 100

Latest directors dealings